

CPRIT Drives Forward Childhood Cancer Research

CPRIT funding has launched 178 research projects focused on childhood cancer

- More than \$308 million in CPRIT grants invested in childhood cancer research and product development
- 11% of CPRIT's portfolio goes to childhood cancer projects—proportionately 3 times the national rate
- 14 Pediatric Cancer Scholars successfully recruited to Texas >\$42 million
- Seven active Core Facilities provide resources and services to childhood cancer researchers
- More than 450 scientific publications and 25 patents resulting from CPRIT-supported childhood cancer research projects

Independent research awards address important childhood cancer topics:

- Molecularly targeted therapies
- Response biomarkers
- Cancer metabolism
- Immune surveillance

- Mechanisms underlying heart toxicity
- Cancer genetic susceptibility
- Cancer prevention: HPV vaccine

Targeting multiple cancer types impacting children

- **Neuroblastoma** –New treatments for neuroblastoma developed with CPRIT grants are in clinical trials with promising impact on survival. (See RP100762)
- Leukemia Cellular therapy for the treatment of children and adults with AML
- Ewing's Sarcoma Over \$20 million in CPRIT funding supporting treatment for the rare bone cancer in clinical trials (See RP190414, RP190539, RP190385, DP160014, RP160487, RP110395)
- **Brain cancer** More than \$46 million invested in childhood brain cancer research, spanning bench, translational and product development research.
- Survivorship Online Patient-Centered Decision Support Service to Empower Childhood Cancer Survivors in Managing Screening and Prevention of Late Effects of Treatment (See PP130070)

Capitalizing on CPRIT's longstanding investment in improving outcomes, Texas is poised to be the world leader in childhood cancer research